Inogen appoints Vafa Jamali to board
Inogen, Inc. has announced the appointment of Vafa Jamali as an independent director to its Board of Directors, effective either on June 15th or the date of the Company’s 2026 Annual Meeting. Jamali brings extensive experience as a medical device executive, having previously served as CEO of ZimVie and held senior roles at Covidien and Medtronic. This appointment is expected to support Inogen's strategic transformation from a single-product oxygen company into a diversified respiratory care platform, focusing on growth, profitability, and product innovation.
Inogen Appoints Vafa Jamali to Board
Inogen, Inc. (Nasdaq: INGN) has announced the appointment of Vafa Jamali, a seasoned medical device executive, to its Board of Directors, effective on the date of the Company’s 2026 Annual Meeting or June 15th if earlier. Jamali's extensive experience, including his tenure as CEO of ZimVie and a senior role at Medtronic, is expected to support Inogen's strategic transformation into a diversified respiratory care platform. This appointment is part of a cooperation agreement with Kent Lake Partners LP, which invested in Inogen to support its path of profitable growth and innovation.
Freedom Broker initiates Inogen stock coverage with buy rating on respiratory platform growth
Freedom Broker has initiated coverage on Inogen, Inc. (NASDAQ:INGN) with a buy rating and a price target of $12.00, suggesting an 89% upside from its current trading price of $6.36. The company, a respiratory-focused medtech provider, is transitioning to a broader respiratory care platform, with growth driven by international expansion, B2B channels, and portfolio diversification. Recent developments include an estimated Q4 2025 revenue increase, a $30 million stock buyback program, the launch of Aurora CPAP masks, and significant leadership changes.
Inogen Adds Director Amid Cooperation Agreement With Shareholder
Inogen (INGN) announced the appointment of Vafa Jamali, a seasoned medical device executive, to its board of directors, effective mid-2026. This appointment coincides with a cooperation agreement between Inogen and shareholder Kent Lake Partners, which includes customary standstill and voting commitments, indicating a strategic alignment as Inogen diversifies its respiratory care platform. Spark, TipRanks' AI Analyst, views INGN as "Neutral" due to its transitional phase, citing strategic positives like improved EBITDA guidance against financial performance challenges.
Inogen (Nasdaq: INGN) names Vafa Jamali director and signs cooperation agreement
Inogen Inc. (Nasdaq: INGN) announced the appointment of Vafa Jamali, a veteran medical device executive, as an independent Class I director to its Board. Concurrently, Inogen entered into a cooperation agreement with Kent Lake entities and Benjamin Natter, which includes provisions for voting alignment and standstill restrictions. Jamali will serve on the Audit and Compliance Committees, bringing his extensive experience to guide Inogen's strategic transformation into a diversified respiratory care platform.
Inogen Announces the Appointment of Vafa Jamali to Board of Directors
Inogen, Inc. (Nasdaq: INGN) has announced the appointment of Vafa Jamali as an independent director to its Board of Directors, effective on the date of the company's 2026 Annual Meeting or June 15th if earlier. Jamali, a seasoned medical device executive, is expected to bring significant expertise to Inogen as it transforms into a diversified respiratory care platform. The appointment is part of a cooperation agreement with Kent Lake Partners LP, Kent Lake PR LLC, and Benjamin Natter, who expressed confidence in Inogen's strategic direction.
Inogen appoints Jason Richardson as CFO to support growth
Inogen, Inc. has announced several leadership appointments, including Jason Richardson as the new Chief Financial Officer, effective April 6, 2026. Richardson, who previously held senior finance roles at Baxter International Inc., succeeds Michael Bourque. The company also appointed Dominic Hulton as Chief Marketing Officer and Corey Moritz as Vice President, U.S. Business to Business Sales, with these changes aimed at accelerating Inogen's growth and strengthening its market presence.
Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
Inogen, Inc. (Nasdaq: INGN) announced that its President and CEO, Kevin Smith, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 10:15 a.m. Eastern Time. A live audio webcast will be available on Inogen's Investor Relations website. Inogen is a medical technology company focusing on innovative respiratory products for homecare settings.
Inogen CEO to speak April 14 at Needham healthcare event
Inogen, Inc. announced that its President and CEO, Kevin Smith, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. The company, which is a medical technology firm specializing in respiratory products, will make a live audio webcast and archived recording of the presentation available on its investor relations website. This announcement also highlights Inogen's commitment to Regulation FD by using its Investor Relations website for disclosing material non-public information.
Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
Inogen, Inc. (Nasdaq: INGN) announced that its President and CEO, Kevin Smith, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. The medical technology company, which specializes in innovative respiratory products for homecare, will make a live audio webcast and archived recording of the presentation available on its investor relations website. The press release also includes forward-looking statements regarding Inogen's future business plans, market opportunities, and financial outlook.
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen, Inc. announced the approval of inducement grants of restricted stock units (RSUs) to its new Chief Financial Officer, Jason Richardson, and Chief Marketing Officer, Dominic Hulton. These equity awards, made under Nasdaq Listing Rule 5635(c)(4), are a material inducement for their employment with the company. The grants include time-based and performance-based RSUs for Mr. Richardson and time-based RSUs for Mr. Hulton, vesting over three years subject to continued service.
Inogen appoints Jason Richardson as CFO; Michael Bourque to step down, remain as Senior Advisor
Inogen has appointed Jason Richardson as its new Executive Vice President, Chief Financial Officer, and Treasurer, effective April 6, 2026. Current CFO Michael Bourque will step down but remain as a Senior Advisor until June 30, 2026. Richardson previously served as CFO and VP of Health System and Technologies Segment at Baxter.
Inogen makes three appointments to exec team
Inogen has appointed three new members to its executive team to accelerate its next phase of growth. Jason Richardson will serve as CFO, Dominic Hulton as chief marketing officer, and Corey Moritz as vice president, U.S. business-to-business sales. These strategic hires bring extensive experience in finance, marketing, and commercial transformation from the medical device and healthcare industries.
Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
Inogen, Inc. (Nasdaq: INGN) announced that its President and CEO, Kevin Smith, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. A live audio webcast and archived recording of the presentation will be available on the company's Investor Relations website. Inogen is a medical technology company specializing in innovative respiratory products for homecare settings.
Inogen appoints new CFO
This article announces that Inogen has appointed a new Chief Financial Officer.
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen, Inc. announced inducement grants of restricted stock units to Jason Richardson, the new Chief Financial Officer, and Dominic Hulton, the new Chief Marketing Officer, in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Richardson received 200,000 RSUs (half time-based, half performance-based), while Mr. Hulton received $200,000 in time-based RSUs. These awards are intended to attract and retain key talent and will vest over three years, subject to continued employment and performance goals for Mr. Richardson.
Inogen (INGN) Reaffirms FY26 Revenue Outlook Amid Market Adjustm
Inogen (INGN) has reaffirmed its fiscal year 2026 revenue forecast, projecting between $366 million and $373 million, aligning with analyst expectations. The company, which specializes in respiratory health products, exhibits mixed financial health with strong gross margins but negative profitability metrics and an Altman Z-Score indicating potential distress. Despite the financial challenges, valuation metrics suggest the stock may be undervalued, and institutional ownership remains high.
Inogen (NASDAQ: INGN) appoints new CFO and growth-focused commercial leaders
Inogen, Inc. (NASDAQ: INGN) announced key leadership changes, including the appointment of Jason Richardson as the new CFO, effective April 6, 2026, succeeding Michael Bourque. The company also appointed Dominic Hulton as Chief Marketing Officer and Corey Moritz as Vice President, U.S. Business to Business Sales, to accelerate its growth strategy. Inogen reaffirmed its first-quarter and full-year 2026 financial outlook, indicating that these executive appointments do not alter its near-term financial expectations.
New Inogen finance and marketing chiefs get stock awards to join
Inogen, Inc. announced inducement stock awards for its new Chief Financial Officer, Jason Richardson, and Chief Marketing Officer, Dominic Hulton. These awards, consisting of restricted stock units (RSUs) and performance-based restricted stock units (PSUs), were granted under Nasdaq Listing Rule 5635(c)(4) to attract the new executives. The grants aim to align the executives' compensation with the company's performance and their continued service.
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen, Inc. announced inducement grants of restricted stock units to its new Chief Financial Officer, Jason Richardson, and Chief Marketing Officer, Dominic Hulton. These awards were approved under Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize their employment with the company. Richardson will receive equity awards covering 200,000 shares, comprising both time-based and performance-based restricted stock units, while Hulton will receive $300,000 in time-based restricted stock units.
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen, Inc. announced the granting of restricted stock units to new hires Jason Richardson, Chief Financial Officer, and Dominic Hulton, Chief Marketing Officer, as an inducement for their employment. These equity awards, approved by the Compensation Committee, are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to attract top talent to the medical technology company. The grants consist of both time-based and performance-based restricted stock units, vesting over three years, and were issued outside of the company's stockholder-approved equity plan.
Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth
Inogen, Inc. has announced several key leadership appointments to accelerate its next phase of growth. Jason Richardson has been named Chief Financial Officer, succeeding Michael Bourque. Dominic Hulton has been appointed Chief Marketing Officer, and Corey Moritz has joined as Vice President, U.S. Business to Business Sales. The company also reaffirmed its financial outlook for the first quarter and full year 2026.
Inogen Inc Stock: Portable Oxygen Leader Faces Profitability Hurdles Amid Aging Population Demand
Inogen Inc, a leader in portable oxygen concentrators, faces profitability challenges despite being in a growing market driven by an aging population and increasing demand for home healthcare. The company's business model relies on direct-to-consumer sales and rentals of its lightweight oxygen devices, with strong potential from recurring revenue and technological advancements. However, it grapples with negative earnings, high R&D costs, and competitive pressures, making execution crucial for future growth and investor confidence.
Inogen (NASDAQ:INGN) Shares Cross Below Two Hundred Day Moving Average - What's Next?
Inogen (NASDAQ:INGN) shares recently fell below their 200-day moving average, trading as low as $6.19, indicating potential bearish momentum. Analysts have a mixed to tepid outlook, with a "Hold" consensus and a $11 price target despite the company beating EPS estimates but missing revenue slightly for the quarter. Institutions have been adjusting their positions, and Inogen remains unprofitable.
Inogen (INGN) up 6.8% since last earnings report: Can it continue?
This article analyzes Inogen's stock performance following its last earnings report, noting a 6.8% increase. It speculates on the potential for this positive trend to continue, prompting investors to consider future prospects.
Vanguard disaggregates holdings; INGN shows 0 shares (INGN)
The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A, reporting zero beneficial ownership of Inogen Inc (INGN) common stock. This change reflects an internal realignment where certain Vanguard subsidiaries will now report beneficial ownership separately. The filing, dated March 13, 2026, and signed on March 27, 2026, indicates 0% ownership of Inogen’s class.
If You Invested $1,000 in Inogen Inc (INGN)
This article analyzes the historical performance of investing $1,000 in Inogen Inc (INGN), a medical technology company specializing in respiratory care devices. It details how such an investment would have fared over 1, 5, and 10 years, showing significant negative returns and underperformance compared to the S&P 500. The article also provides an overview of Inogen Inc's business, product portfolio, market positioning, and financial characteristics.
Inogen Inc Stock (ISIN: US45780L1044) Faces Headwinds Amid Portable Oxygen Slowdown
Inogen Inc., a leader in portable oxygen concentrators, is experiencing a slowdown in its core business due to weakening demand and margin pressures. The company's recent quarterly results showed softer-than-expected demand, especially in the US domestic market, despite growth in international sales. Investors, particularly those in the DACH region, are closely watching how Inogen navigates these challenges, including reimbursement complexities and efforts to stabilize sales.
CSM Advisors LLC Buys Shares of 364,100 Inogen, Inc $INGN
CSM Advisors LLC has acquired a new position in Inogen, Inc (NASDAQ:INGN), purchasing 364,100 shares valued at approximately $2,973,000 during the third quarter. This makes CSM Advisors LLC one of several institutional investors that have recently adjusted their holdings in the medical technology company. Inogen's stock recently opened at $6.13, with a market capitalization of $166.93 million, and analysts are predicting an EPS of -1.73 for the current fiscal year.
Inogen, Inc $INGN Shares Sold by Divisadero Street Capital Management LP
Divisadero Street Capital Management LP significantly reduced its stake in Inogen (NASDAQ:INGN) by 80.6% in the third quarter, selling over 367,000 shares. Despite Inogen beating EPS estimates last quarter, it missed revenue expectations and maintains negative margins. Analyst sentiment for the medical technology company remains mixed, with a consensus "Hold" rating and an average price target of $11.00.
Short Interest in Inogen, Inc (NASDAQ:INGN) Expands By 24.2%
Short interest in Inogen, Inc. (NASDAQ:INGN) grew by 24.2% in February, reaching 1,208,558 shares, which represents 4.5% of the company's stock. Institutional investors hold 89.94% of Inogen's stock, with some increasing their positions and others establishing new ones. Despite reporting better-than-expected Q4 EPS, the medical technology company faces negative margins and a "Hold" rating from analysts, with shares trading around $6.06.
Inogen Inc expected to post a loss of 27 cents a share - Earnings Preview
Inogen Inc (INGN) is projected to report a loss of 27 cents per share with a 2.1% increase in revenue to $90.6 million for the quarter ending June 30, 2025. This forecast is based on an average estimate from three analysts, with the company's own guidance for the period ranging between $89.00 million and $91.00 million. Analysts currently rate INGN as a "hold," with a median 12-month price target of $13.00.
Inogen (INGN) CCO reports RSU vesting and 20,000-unit grant
Inogen's Chief Commercial Officer, Gregoire Ramade, recently engaged in equity compensation activities. This included the exercise of 13,005 restricted stock units (RSUs) into common stock and the withholding of 6,022 shares to cover tax liabilities. Additionally, Ramade received a new grant of 20,000 RSUs, which will vest in annual installments over three years, contingent on his continued service.
Inogen Announces Participation in the KeyBanc Virtual Life Sciences & MedTech Investor Forum
Inogen, Inc. announced that its President and CEO, Kevin Smith, will participate in a virtual fireside chat at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 17, 2026. The event will be webcast live and archived on Inogen's Investor Relations website. The company also reiterated its commitment to using its investor relations website for disclosing material non-public information.
Inogen (INGN) EVP Kevin P. Smith reports RSU grants and tax share withholding
Inogen EVP Kevin P. Smith reported equity compensation, including a grant of 35,000 restricted stock units (RSUs) on February 27, 2026, and the exercise of 14,005 RSUs into common stock on March 1, 2026. He also received 1,500 shares of common stock and had 6,276 shares disposed to cover tax withholdings related to vested RSUs. After these transactions, Smith directly held 22,007 shares of common stock and a remaining RSU balance.
[Form 4] Inogen Inc Insider Trading Activity
Inogen Inc's VP and Chief Accounting Officer, Mary E. Wright, reported several equity compensation transactions detailed in a recent Form 4 SEC filing. These included the exercise or conversion of restricted stock units into common stock, grants of common stock, and shares withheld for tax liabilities. A new grant of 8,000 restricted stock units was also awarded, vesting over several years.
Inogen (INGN) CEO receives 90,000 RSU grant and reports tax share withholdings
Inogen Inc.'s CEO, Kevin Raymond Merrill Smith, received a grant of 90,000 restricted stock units (RSUs) on February 27, 2026, which will vest over three years. He also had performance-based and time-based RSUs vest on March 1, 2026, leading to share acquisitions and subsequent share withholdings to cover tax liabilities. This information was reported in a recent SEC Form 4 filing.
Inogen Inc (INGN) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Initiatives
Inogen Inc (INGN) reported a 4% year-over-year revenue growth for fiscal year 2025, reaching $348.7 million, and achieved a positive adjusted EBITDA of $2.7 million for the first time since 2021. While international sales grew by nearly 15% in Q4 2025, US sales and rental revenue saw declines, partly due to the timing of large customer orders and shifts in sales channels. The company maintains a strong balance sheet with $120.9 million in cash and no debt, and anticipates 6% revenue growth in 2026.
INGN Financials: Income Statement, Balance Sheet & Cash Flow
Inogen Inc.'s (INGN) financial performance in fiscal year 2025 showed modest revenue growth of 3.9% to $348.7M, but the company remained unprofitable with a net income of -$22.7M and negative free cash flow of -$13.7M. Despite these profitability challenges, Inogen maintains a strong balance sheet with low debt ($0.55 D/E ratio) and high liquidity (3.12 current ratio), scoring 46 out of 100 on its Financial Profile. The company's earnings quality is considered low, with operating cash flow significantly lower than reported earnings.
Inogen Announces $30 Million Share Repurchase Program
Inogen, Inc. announced a share repurchase program worth up to $30 million of its common stock, authorized by its Board of Directors. This move reflects the company's confidence in its strategy, progress towards profitability, and long-term growth trajectory, according to CEO Kevin Smith. The program will be funded by cash flow and existing cash reserves and is set to expire by December 31, 2027, or when the maximum amount is utilized.
Inogen hits profitability milestone, grows TAM sixfold with new respiratory products
Inogen achieved adjusted EBITDA profitability in 2025 for the first time since 2021, reporting $2.7 million for the year and authorizing a $30 million share repurchase program. The company has diversified its product portfolio beyond portable oxygen concentrators to include sleep therapy, airway clearance, and digital health solutions, expanding its total addressable market sixfold to $3.4 billion. Inogen plans annual new product launches, anticipating high single-digit revenue growth and over 10% adjusted EBITDA within the next three to five years.
Inogen (INGN) Quarterly Losses Persist And Test Bullish Margin Recovery Narratives
Inogen (INGN) reported Q4 FY 2025 revenue of US$81.7 million and a basic EPS loss of US$0.26, with trailing twelve-month net losses of US$22.7 million. The company continues to face margin pressure and is not expected to achieve profitability in the next three years, challenging bullish narratives despite some revenue growth and an improved EPS loss compared to the previous year. Analysts present both bull and bear cases, focusing on the company's low P/S multiple versus persistent losses and modest revenue growth.
Inogen, Inc. (NASDAQ:INGN) Q4 2025 Earnings Call Transcript
Inogen, Inc. reported its Q4 2025 earnings, exceeding EPS expectations at $-0.26 against an anticipated $-0.36. The company achieved $81.7 million in Q4 revenue and $348.7 million for the full year 2025, marking 4% year-over-year growth. Key highlights include returning to adjusted EBITDA profitability for the first time since 2021, significant progress in diversifying its product portfolio beyond oxygen concentrators into sleep therapy, airway clearance, and digital health, and the initiation of a $30 million share repurchase program.
Inogen (INGN) Initiates $30 Million Share Buyback Program
Inogen Inc. (INGN) has announced a $30 million share repurchase program, signaling management's confidence in the company's strategic direction and long-term potential. Despite a mixed financial performance with revenue decline and negative profitability, Inogen maintains a strong, debt-free balance sheet. The medical technology company, specializing in portable oxygen concentrators, faces both opportunities and challenges that investors should consider.
Inogen Stock Dips Despite Q4 Earnings Beat, Revenues Up Y/Y
Inogen (INGN) reported a narrower-than-expected loss per share and an earnings beat for Q4 2025, with revenues up 2% year-over-year to $81.7 million, driven by strong international performance. Despite these positive indicators, the stock dipped by almost 5%. The company also provided revenue guidance for Q1 and full-year 2026, alongside news of product portfolio expansion and strategic collaborations.
Inogen Stock Dips Despite Q4 Earnings Beat, Revenues Up Y/Y
Inogen, Inc. (INGN) reported a narrower-than-expected loss per share of 15 cents for Q4 2025, beating the Zacks Consensus Estimate, with revenues up 2% year-over-year to $81.7 million, though slightly missing expectations. The stock dipped despite the beat, primarily due to lower U.S. sales and rental revenue offsetting strong international performance. The company also provided revenue guidance for Q1 and full-year 2026 and announced new product launches and a strategic collaboration.
Inogen Announces $30 Million Share Repurchase Program
Inogen, Inc. announced that its Board of Directors has authorized a share repurchase program for up to $30 million of its outstanding common stock. The company views this program as a way to deploy capital to support continued innovation and portfolio expansion while enhancing shareholder value, reflecting confidence in its strategy and progress towards profitability. The program will be financed through cash flow and existing cash reserves and will expire on December 31, 2027, or once the maximum amount is utilized.
Inogen Inc earnings beat by $0.07, revenue fell short of estimates
Inogen Inc (NASDAQ: INGN) reported fourth-quarter EPS of $-0.26, beating analyst estimates by $0.07, but its revenue of $81.7M fell short of the consensus estimate of $88.6M. The company provided FY 2026 revenue guidance of $366.00M-$373.00M, which is below the analyst consensus of $385.20M. Inogen's stock price has declined significantly over the past 3 and 12 months, and its financial health is rated as "fair performance" by InvestingPro.
Inogen Inc (NASDAQ:INGN) Stock Falls on Revenue Miss and Cautious 2026 Outlook
Inogen Inc (NASDAQ:INGN) reported mixed Q4 2025 financial results, with earnings beating estimates but revenue falling short. The company also provided a cautious outlook for 2026, with revenue guidance significantly below analyst expectations, leading to a sharp decline in its stock price. Despite operational improvements and a positive adjusted EBITDA for the full year, investors are concerned about the slower growth trajectory.
Inogen Inc recently announced its revenue forecast for fiscal year 2026.
Inogen Inc has announced its revenue forecast for fiscal year 2026, projecting figures between $366 million and $373 million. This information was reported by 老虎证券 on February 24, 2026, and is presented as the author's opinion, not investment advice.
